Roivant (ROIV) Q1 FY27 earnings call

Roivant is entering a period of significant catalysts, highlighted by the imminent potential launch of brepocitinib for dermatomyositis and multiple pipeline data readouts in the second half of 2026. The company is strategically preparing for a "slow and steady" launch for brepocitinib, focusing on long-term market development across multiple indications. Financial strength was bolstered by a $950 million Moderna settlement payment, enabling substantial share repurchases, while R&D investments continue to drive a rich pipeline with numerous potential registrational events and filings anticipat